Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX464 in moderate to severe rheumatoid arthritis
NCT04049448Phase 2Completed
- Sponsor
- Abivax
- Start
- Oct 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of obefazimod in rheumatoid arthritis (RA), sponsored by Abivax. Started Oct 2019; status: completed.
02
Drugs
obefazimod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04049448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049448.